Approaching healthcare innovation with ingenuity, passion and courage to create new solutions to difficult medical challenges. Guidelines: bit.ly/3CMYyZW
We’ve shared additional data with the @US_FDA to support the review of our November 5, 2021 #COVID19#vaccine pediatric EUA submission. We request that the FDA schedule a VRBPAC meeting. Additional vaccine options for children are crucial – one approach is not enough.
Hi @ABonTV @NewsNationNow great #morninginamerica interview w/ Dr Fauci today. Just clarifying that we submitted an emergency use authorization (EUA) application for COVAXIN #vaccine candidate to @US_FDA on Nov 5, 2021 for ages 2-18. It’s now under review bit.ly/3sJrxuB
#BREAKING:@WHO granted Emergency Use Listing approval to #COVID-19 vaccine COVAXIN™, developed by our partner @BharatBiotech. We are pleased this vaccine now has the potential to protect millions more people around the world from severe COVID-19 disease. ow.ly/GVq450GFcqB
We’re pleased to share that the @US_FDA lifted the clinical hold on our Investigational New Drug (IND) application for our #COVID19#vaccine candidate. We are eager to move forward! Read more: bit.ly/3LUZ3Fw
The B.1.617 variant, which is effectively neutralized by #COVAXIN, has triggered a 2nd wave of #COVID-19 cases rapidly spreading in 17 countries including the US, according to @WHO. For more information, visit: bit.ly/332qnfH.
We’ve filed an EUA application with the @US_FDA to seek emergency use authorization of our investigational #COVID-19 vaccine candidate for children ages 2-18 in the US. It is being administered under emergency use authorization in 17 countries. Learn more: ow.ly/4SXe50GGQ72
We’re pleased to announce that we have expanded our exclusive commercialization rights for our #COVID19 vaccine to Mexico. Already approved for emergency use in adults in Mexico, it’s under review for emergency use in children 2-18. Read more: bit.ly/3uSJs2s
We’re proud to share that the first patient has been dosed in the Phase 1/2 clinical trial of our modifier #genetherapy candidate for the treatment of #retinitispigmentosa. Find out more about this exciting milestone: bit.ly/3qUy1VM
We’re pleased to share that the results of our study conducted at @EmoryUniversity showing that a booster dose of our #COVID19#vaccine candidate neutralizes Omicron and Delta variants are now published on @medrxivpreprint. Read more: bit.ly/32H5KJx
